Literature DB >> 2567214

Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.

H Gotoh1, M Hagihara, T Nagatsu, H Iwata, T Miura.   

Abstract

We examined the activities of peptidases in synovial fluid from patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Dipeptidyl peptidase IV (DPP IV) activity was lower in synovial fluid from patients with RA, in contrast to the increase of DPP II activity in synovial fluid, as compared with OA. The DPP II/DPP IV ratio for synovial fluid was significantly higher in patients with RA than in patients with OA. A significant correlation was observed between the DPP II/DPP IV ratio for synovial fluid from patients with RA and the amount of C-reactive protein reaction. These results may be useful in the diagnosis of joint effusion of unknown origin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2567214

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  19 in total

1.  Dynamic reorientation of cortical microtubules, from transverse to longitudinal, in living plant cells.

Authors:  M Yuan; P J Shaw; R M Warn; C W Lloyd
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

2.  Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.

Authors:  Jong-Mi Seong; Jeong Yee; Hye Sun Gwak
Journal:  Br J Clin Pharmacol       Date:  2019-06-04       Impact factor: 4.335

3.  Arthritis diagnosis based upon the near-infrared spectrum of synovial fluid.

Authors:  R A Shaw; S Kotowich; H H Eysel; M Jackson; G T Thomson; H H Mantsch
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 4.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

5.  Role of the neutrophil chemorepellent soluble dipeptidyl peptidase IV in decreasing inflammation in a murine model of arthritis.

Authors:  Sarah E Herlihy; Monica L Brown; Darrell Pilling; Brad R Weeks; Linda K Myers; Richard H Gomer
Journal:  Arthritis Rheumatol       Date:  2015-10       Impact factor: 10.995

6.  Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.

Authors:  Premarani Sinnathurai; Wendy Lau; Ana Julia Vieira de Ribeiro; William W Bachovchin; Helen Englert; Graydon Howe; David Spencer; Nicholas Manolios; Mark D Gorrell
Journal:  Int J Rheum Dis       Date:  2016-12-19       Impact factor: 2.454

Review 7.  The evolution of proteinase substrates with special reference to dipeptidylpeptidase IV.

Authors:  R E Smith; C J Reynolds; E A Elder
Journal:  Histochem J       Date:  1992-09

8.  Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.

Authors:  Seoyoung C Kim; Sebastian Schneeweiss; Robert J Glynn; Michael Doherty; Allison B Goldfine; Daniel H Solomon
Journal:  Ann Rheum Dis       Date:  2014-06-11       Impact factor: 19.103

Review 9.  Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins.

Authors:  L Wagner; C Klemann; M Stephan; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2016-03-02       Impact factor: 4.330

Review 10.  Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?

Authors:  Aleksi Sedo; Jonathan S Duke-Cohan; Eva Balaziova; Liliana R Sedova
Journal:  Arthritis Res Ther       Date:  2005-10-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.